2.365
Alector Inc stock is traded at $2.365, with a volume of 228.94K.
It is down -1.05% in the last 24 hours and up +55.59% over the past month.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
See More
Previous Close:
$2.39
Open:
$2.39
24h Volume:
228.94K
Relative Volume:
0.23
Market Cap:
$264.07M
Revenue:
$21.05M
Net Income/Loss:
$-142.93M
P/E Ratio:
-1.7021
EPS:
-1.3895
Net Cash Flow:
$-184.07M
1W Performance:
+0.21%
1M Performance:
+55.59%
6M Performance:
-2.67%
1Y Performance:
-1.05%
Alector Inc Stock (ALEC) Company Profile
Name
Alector Inc
Sector
Industry
Phone
415-231-5660
Address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ALEC
Alector Inc
|
2.365 | 252.34M | 21.05M | -142.93M | -184.07M | -1.3895 |
|
VRTX
Vertex Pharmaceuticals Inc
|
541.86 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.05 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,030.44 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
136.44 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
206.79 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-10-26 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-22-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-22-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-22-25 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-22-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-28-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-17-24 | Downgrade | Mizuho | Outperform → Neutral |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-29-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-26-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-14-23 | Upgrade | Stifel | Hold → Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Sep-25-23 | Initiated | Goldman | Sell |
| Sep-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-13-22 | Initiated | Goldman | Sell |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Sep-27-21 | Initiated | William Blair | Outperform |
| Jan-15-21 | Resumed | BofA Securities | Buy |
| Jun-24-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-19-20 | Initiated | Stifel | Buy |
| Nov-21-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | Barclays | Overweight |
| Mar-04-19 | Initiated | BofA/Merrill | Buy |
| Mar-04-19 | Initiated | Morgan Stanley | Overweight |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
View All
Alector Inc Stock (ALEC) Latest News
Alector (ALEC) CEO shifts 2.1M shares into family trusts - Stock Titan
Alector (ALEC) Results at a Glance: EPS Lands Above Forecast in Latest Trading; Latest Reaction: Shares Finish 9.95% Higher on the DayFree Cash Flow Trends - vinanet.vn
Merck & Co. Inc. Makes New $7.13 Billion Investment in Alector, Inc. $ALEC - MarketBeat
Alector, Inc. (NASDAQ:ALEC) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
ALEC Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseHigh Estimate Range - vinanet.vn
Industry Analysts Just Upgraded Their Alector, Inc. (NASDAQ:ALEC) Revenue Forecasts By 60% - simplywall.st
HC Wainwright Issues Negative Outlook for Alector Earnings - MarketBeat
BofA Securities Maintains Alector(ALEC.US) With Sell Rating, Announces Target Price $1 - Moomoo
Bank of America Securities Sticks to Its Sell Rating for Alector (ALEC) - The Globe and Mail
H.C. Wainwright Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $5 - moomoo.com
Analysts Offer Insights on Healthcare Companies: Alector (ALEC), Genmab (GMAB) and Xenon (XENE) - The Globe and Mail
TD Cowen Maintains Alector(ALEC.US) With Hold Rating - Moomoo
Alector Inc (ALEC) Stock News Today - TradingKey
Alector Inc (ALEC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alector (ALEC) Declines 2.73% to $1.78 as Key Support at $1.69 Comes into FocusMFI Overbought - vinanet.vn
Alector earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Alector (NASDAQ:ALEC) Releases Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Alector, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Alector: Q2 Earnings Snapshot - Barchart.com
Alector, Inc. 2Q 2026: Revenue $3.32M, EPS $(0.21) — 10-Q Summary - TradingView
Alector | 10-Q: Q2 2026 Earnings Report - Moomoo
Alector (NASDAQ: ALEC) details Q2 loss, GSK exit and ABC pipeline focus - Stock Titan
Alector, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Alector reports Q2 2026: $172.8M cash; Q2 net loss $23.0M - TradingView
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Primer: Alector Inc (ALEC US)Aug 2026 - Smartkarma
Alector Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Enterprise value to EBITDA forward of Alector, Inc. – NASDAQ:ALEC - TradingView
Alector (ALEC) Expected to Post Quarterly Earnings on Thursday - MarketBeat
Alector Inc (ALEC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alector Inc (ALEC) Institutional Confidence - TradingKey
Alector Inc (ALEC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alector (ALEC) Rises 2% as Stock Holds Above Key SupportETF AUM Growth - vinanet.vn
Alector Inc (ALEC) Balance Sheet - TradingKey
Alector Inc (ALEC) Cash Flow - TradingKey
Alector Inc (ALEC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
ALEC|Alector Inc|Price:1.480|Chg%:-0.010 - TradingKey
Alector Inc (ALEC) Income Statement - TradingKey
Alector Inc (ALEC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ALEC|Alector Inc|Price:1.510|Chg%:-0.110 - tradingkey.com
Spruce Street Capital LP Buys 983,082 Shares of Alector, Inc. $ALEC - MarketBeat
Alector, Inc. Revenue Breakdown – NASDAQ:ALEC - TradingView
Alector (ALEC) Hovers Near Support Amid Modest DeclineBollinger Band - dars.gov.et
ALEC Q1 2026 Earnings: Better-than-Expected Loss as Alector Advances PipelineEarnings Seasonality - dars.gov.et
Alector (ALEC) Q1 2026 Earnings: Narrower-Than-Expected Loss Sparks OptimismEPS Guidance Update - vinanet.vn
Alector (ALEC) Goldman Sachs 45th Annual Global Healthcare Conference Summary - Quartr
Alector (ALEC) Proxy filing Summary - Quartr
ALEC Q1 2026 Earnings: Better-Than-Expected Loss Despite No RevenueEarnings Power Value - vinanet.vn
Alector Q1 2026 Earnings: Narrower Loss Surprises, Yet Shares Dip Amid Revenue AbsenceCapex Guidance - DonanımHaber
Alector Inc Stock (ALEC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):